DD209575A5 - Verfahren zur herstellung eines pharmazeutischen produktes in anhaltend freisetzender form - Google Patents

Verfahren zur herstellung eines pharmazeutischen produktes in anhaltend freisetzender form Download PDF

Info

Publication number: DD209575A5
Authority: DD; German Democratic Republic
Prior art keywords: film; item; polymer; solution; active substance
Prior art date: 1982-04-15

Application number

DD83249876A

Other languages

German (de)

English (en)

Inventor

Paolo Colombo

Ubaldo Conte

Original Assignee

Prophin Lab Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-15

Filing date

1983-04-14

Publication date

1984-05-16

1983-04-14 Application filed by Prophin Lab Spa filed Critical Prophin Lab Spa

1984-05-16 Publication of DD209575A5 publication Critical patent/DD209575A5/de

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
229940127557 pharmaceutical product Drugs 0.000 title claims description 5
238000004519 manufacturing process Methods 0.000 title abstract description 10
239000003814 drug Substances 0.000 claims abstract description 37
238000000034 method Methods 0.000 claims abstract description 20
238000009792 diffusion process Methods 0.000 claims abstract description 14
239000013543 active substance Substances 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims abstract description 8
229920000642 polymer Polymers 0.000 claims description 40
229940079593 drug Drugs 0.000 claims description 35
239000004480 active ingredient Substances 0.000 claims description 20
239000000243 solution Substances 0.000 claims description 20
239000012730 sustained-release form Substances 0.000 claims description 17
239000001913 cellulose Substances 0.000 claims description 11
229920002678 cellulose Polymers 0.000 claims description 11
229920000058 polyacrylate Polymers 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
230000002378 acidificating effect Effects 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 6
230000001681 protective effect Effects 0.000 claims description 6
229920002554 vinyl polymer Polymers 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
239000003960 organic solvent Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
229920006243 acrylic copolymer Polymers 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229920006163 vinyl copolymer Polymers 0.000 claims description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
238000005507 spraying Methods 0.000 claims description 2
229920002988 biodegradable polymer Polymers 0.000 claims 4
239000004621 biodegradable polymer Substances 0.000 claims 4
241000282376 Panthera tigris Species 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
238000001704 evaporation Methods 0.000 claims 1
230000008961 swelling Effects 0.000 claims 1
239000012528 membrane Substances 0.000 abstract description 9
230000000694 effects Effects 0.000 abstract description 3
238000009472 formulation Methods 0.000 abstract description 2
238000010521 absorption reaction Methods 0.000 abstract 1
239000011159 matrix material Substances 0.000 description 11
229960005344 tiapride Drugs 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000000126 substance Substances 0.000 description 9
229960004166 diltiazem Drugs 0.000 description 7
239000000454 talc Substances 0.000 description 7
235000012222 talc Nutrition 0.000 description 7
229910052623 talc Inorganic materials 0.000 description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
230000035699 permeability Effects 0.000 description 6
JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 5
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
239000004205 dimethyl polysiloxane Substances 0.000 description 4
238000001035 drying Methods 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
238000005303 weighing Methods 0.000 description 4
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229910052802 copper Inorganic materials 0.000 description 3
239000010949 copper Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
OTFDPNXIVHBTKW-UHFFFAOYSA-N Tiapride hydrochloride Chemical compound [Cl-].CC[NH+](CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC OTFDPNXIVHBTKW-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
229960005316 diltiazem hydrochloride Drugs 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000004080 punching Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
238000007605 air drying Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000006065 biodegradation reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000004898 kneading Methods 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DD83249876A 1982-04-15 1983-04-14 Verfahren zur herstellung eines pharmazeutischen produktes in anhaltend freisetzender form DD209575A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT20758/82A IT1153487B (it)	1982-04-15	1982-04-15	Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli

Publications (1)

Publication Number	Publication Date
DD209575A5 true DD209575A5 (de)	1984-05-16

Family

ID=11171631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD83249876A DD209575A5 (de)	1982-04-15	1983-04-14	Verfahren zur herstellung eines pharmazeutischen produktes in anhaltend freisetzender form

Country Status (6)

Country	Link
EP (1)	EP0092060B1 (fr)
JP (1)	JPS58189111A (fr)
AT (1)	ATE23266T1 (fr)
DD (1)	DD209575A5 (fr)
DE (1)	DE3367324D1 (fr)
IT (1)	IT1153487B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE55745B1 (en) *	1983-04-06	1991-01-02	Elan Corp Plc	Sustained absorption pharmaceutical composition
US5364620A (en) *	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
IT1206166B (it) *	1984-07-26	1989-04-14	Sigma Tau Ind Farmaceuti	Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
ZA86252B (en) *	1985-01-30	1986-09-24	Warner Lambert Co	Coated dosage forms
US4600645A (en) *	1985-01-31	1986-07-15	Warner-Lambert Company	Process for treating dosage forms
EP0212746B1 (fr) *	1985-08-16	1991-04-10	The Procter & Gamble Company	Particules pour une libération constante de la substance active
DE3678644D1 (de) *	1985-08-16	1991-05-16	Procter & Gamble	Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
DE3678641D1 (de) *	1985-08-16	1991-05-16	Procter & Gamble	Partikel mit konstanter wirkstofffreisetzung.
JPS6261916A (ja) *	1985-09-12	1987-03-18	Fujisawa Pharmaceut Co Ltd	持続性製剤
IE63321B1 (en) *	1986-02-03	1995-04-05	Elan Corp Plc	Drug delivery system
IL88083A (en) *	1987-11-06	1992-11-15	Tanabe Seiyaku Co	Controlled release pharmaceutical dosage form and its preparation
DE3812799A1 (de) *	1988-04-16	1989-10-26	Sanol Arznei Schwarz Gmbh	Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
US4859470A (en) *	1988-06-02	1989-08-22	Alza Corporation	Dosage form for delivering diltiazem
US5169642A (en) *	1988-06-24	1992-12-08	Abbott Laboratories	Sustained-release drug dosage units
US5268182A (en) *	1988-06-24	1993-12-07	Abbott Laboratories	Sustained-release drug dosage units of terazosin
AU2008286914B2 (en)	2007-08-13	2014-10-02	Ohemo Life Sciences Inc.	Abuse resistant drugs, method of use and method of making
US20140275149A1 (en)	2013-03-15	2014-09-18	Inspirion Delivery Technologies, Llc	Abuse deterrent compositions and methods of use
US10729685B2 (en)	2014-09-15	2020-08-04	Ohemo Life Sciences Inc.	Orally administrable compositions and methods of deterring abuse by intranasal administration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3909444A (en) *	1971-08-05	1975-09-30	Ncr Co	Microcapsule
GB1468172A (en) *	1973-03-28	1977-03-23	Benzon As Alfred	Oral drug preparations
JPS5541205B2 (fr) *	1973-04-20	1980-10-22
IT1115596B (it) *	1978-03-13	1986-02-03	Bayer Italia Spa	Metodo per la preparazione di microgranuli gastoresistenti ed enterosolubili di sostanze farmaceutiche,in particolare di sostanze proteiche e microgranuli preparati con detto metodo
US4252786A (en) *	1979-11-16	1981-02-24	E. R. Squibb & Sons, Inc.	Controlled release tablet
JPS5873359A (ja) *	1981-10-27	1983-05-02	旭化成株式会社	医薬錠剤の製造方法

1982
- 1982-04-15 IT IT20758/82A patent/IT1153487B/it active
1983
- 1983-03-21 AT AT83102781T patent/ATE23266T1/de not_active IP Right Cessation
- 1983-03-21 DE DE8383102781T patent/DE3367324D1/de not_active Expired
- 1983-03-21 EP EP83102781A patent/EP0092060B1/fr not_active Expired
- 1983-04-14 DD DD83249876A patent/DD209575A5/de unknown
- 1983-04-15 JP JP58065789A patent/JPS58189111A/ja active Pending

Also Published As

Publication number	Publication date
EP0092060B1 (fr)	1986-11-05
ATE23266T1 (de)	1986-11-15
IT8220758A0 (it)	1982-04-15
IT8220758A1 (it)	1983-10-15
EP0092060A1 (fr)	1983-10-26
DE3367324D1 (en)	1986-12-11
IT1153487B (it)	1987-01-14
JPS58189111A (ja)	1983-11-04

Publication	Publication Date	Title
DE69331806T2 (de)	2003-01-16	Multipartikel-arzneistoffabgabesystem mit stossweiser freisetzung
EP0069259B1 (fr)	1985-01-09	Forme retard de bromhexine et procédé de préparation
DE69323428T2 (de)	1999-09-02	Morphinzubereitungen mit kontrollierter freisetzung
DD209575A5 (de)	1984-05-16	Verfahren zur herstellung eines pharmazeutischen produktes in anhaltend freisetzender form
DE69526225T2 (de)	2003-01-09	Zusammensetzung enthaltend morphin, polyvinylpyrrolidon und ein polyalkylenoxid
DE69917866T2 (de)	2005-07-07	Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
DE68908297T2 (de)	1994-03-31	Formgepresste Zusammensetzungen.
DE69020758T2 (de)	1995-12-07	Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen.
DE69101314T2 (de)	1994-06-09	Dosierungsform zur verabreichung eines arzneimittels an die därme.
DE69636223T2 (de)	2007-04-19	Formulierung mit gesteuerter Freisetzung für wasserlösliche Arzneistoffe, in der eine Auslauföffnung in Situ gebildet wird
DE69720055T2 (de)	2003-09-11	Verabreichungsform zur abgabe von steigenden wirkstoffdosen
DE69525148T2 (de)	2002-09-05	Pharmazeutische formulierung
DE69924710T2 (de)	2005-09-15	Pharmazeutische zubereitung zur anwendung in der antiasthmatherapie
EP0032562B1 (fr)	1984-03-14	Formes-retard pour l'administration du dipyridamol et procédés pour leur préparation
DE3850340T2 (de)	1994-10-27	Zahlreiche kleine Pillen in flüssiger Darreichungsform.
DE69330910T2 (de)	2002-04-04	Arzneiabgabesystem mit stossweiser freisetzung von partikeln
DE69230112T2 (de)	2000-03-02	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69825165T2 (de)	2005-07-14	Arzneimittelform mit zwei überzugs-schichten
CH636276A5 (de)	1983-05-31	Durch osmose betaetigbare abgabevorrichtung.
EP1113787B1 (fr)	2004-03-03	Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production
DE69221711T2 (de)	1998-03-12	Verabreichungsvorrichtung von Wirkstoffdispersionen mit kontrollierter Freisetzung
CH690955A5 (de)	2001-03-15	Oxybutynin umfassende Arzneiform.
LU81503A1 (de)	1980-08-08	Arzneimittel-retardform mit unloeslichen poroesen diffusioshuellen
CH672736A5 (fr)	1989-12-29
DE3884214T2 (de)	1994-01-13	Verfahren zur herstellung einer festen form mit beibehaltender freisetzung aus einer funktionellen aktiven komposition und die bei dem verfahren erhaltene dosierungsform.